Abstract:Despite remarkable advances in the field of oncology, cancer continues to be a leading cause of mortality worldwide [1] . Growing evidence points to the emergence of dormant cells as a contributor to the disease's aptitude to evade therapeutic interventions [2,3▪,4,5,6▪] . In this context, cellular dormancy refers to cells entering a prolonged state of reduced proliferation, where growth is considerably slowed down or halted [7▪,8] . This concept overlaps largely with other programs of proliferative arrest, specifically quiescence (i.e. the reversible state of G0/G1 cell cycle arrest) and replicative senescence (i.e. the cessation of cell division due to cellular aging and replication limits) [9▪] . Beyond proliferation, the phenotypic switch of cellular dormancy is characterized by a substantial decrease in biosynthetic activity, such as RNA transcription and protein translation [10,11] . Concomitantly, dormant cells appear to undergo a deep metabolic rewiring, as energy and metabolite requirements are often linked to growth and proliferation [12,13] .

Unveiling the role of cellular dormancy in cancer progression and recurrence